MOTIVATION LETTER The European Commission faces a structural challenge in health policy: how to regulate technologies that evolve faster than the evidence base that supports them. Digital therapeutics, AI-assisted drug discovery, and computational pharmacology are no longer speculative. They are deployed in clinics and laboratories across Europe today. My research sits at the intersection of these domains, and I want to bring that technical grounding to the Commission's policy-making environment. I am a Nigerian pharmacist and computational researcher, currently enrolled in the M.Sc. Digital Health programme at the Hasso Plattner Institute in Potsdam, Germany. My independent research spans addiction neuroscience, protein-machine learning, and dynamical-systems pharmacology. I have developed the Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention in addiction. This model uses a three-coupled-axis ODE system, calibrated with Bayesian MCMC on 14 free parameters drawn from a literature screen of 1,847 records. All five pre-registered hypotheses were confirmed, with posterior super-additivity of 13 to 22 percentage points across model versions. The work is documented in three sole-authored preprints on OSF and Zenodo, and a co-authored paper is under review at Alcohol. I have also led a replication study on topological data analysis for hERG cardiotoxicity prediction. The study was pre-registered and powered. It found that bipartite persistent homology features do not beat a plain descriptor baseline, settling a comparison the published literature had never actually run. My current project, TOPOLOGIX, uses ESM-2 protein-language-model delta-embeddings combined with Morgan fingerprints and a Random Forest classifier to predict drug-resistance mutations from sequence alone. It achieves an AUROC of 0.804 on the Platinum benchmark, covering 100 percent of mutations compared to roughly 18 percent for structure-limited tools. These projects required me to work across pharmacology, computational modeling, and software engineering without institutional supervision. I built four independent DuckDB-based ingest-to-analyze pipelines for life sciences, tech security, and social science domains. I self-host local LLM serving for research workflows. I manage production systems on Linux VPS with systemd, Caddy TLS, and automated backup recovery. This independence is directly relevant to the Blue Book Traineeship. The Commission needs staff who can evaluate technical claims without relying on external consultants, who can read a pre-registration protocol and assess whether the conclusions follow from the data. I have endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. These researchers work on reward learning, computational psychiatry, and reinforcement learning. Their support reflects the rigor of my methods and the relevance of my questions to the broader neuroscience community. I am a non-EU national with a B.Pharm from the University of Ibadan, a PCN license, and a current enrolment in a German M.Sc. programme. I speak English fluently and have experience working across Nigerian and German institutional contexts. I can bring a perspective on how digital health technologies are adopted in lower-resourced settings, and how EU policy frameworks can account for that variation. I want to contribute to the Commission's work on health technology assessment, digital health regulation, or research and innovation policy. The Blue Book Traineeship is the most direct route to understand how the Commission translates evidence into regulation. I am ready to apply my computational and pharmacological training to that task. SHORT ESSAY: RELEVANCE OF MY BACKGROUND TO EU POLICY AREAS The European Union has committed to the European Health Data Space and the AI Act, two regulatory frameworks that will shape how computational tools are validated and deployed in healthcare. My research directly addresses the technical questions these frameworks raise. The CCT model for addiction prevention is relevant to the EU's mental health strategy and its work on substance use disorders. The model formalizes how pharmacological interventions can prevent reward-memory encoding, which is the mechanism underlying relapse. The Bayesian calibration method I used is the same approach the European Medicines Agency recommends for model-informed drug development. I can help the Commission evaluate whether such models meet the standards of evidence required for regulatory approval. The TOPOLOGIX project on drug-resistance prediction is relevant to the EU's antimicrobial resistance action plan. The model covers 100 percent of mutations, compared to roughly 18 percent for structure-based tools. This means it can predict resistance for mutations that have no solved protein structure. The Commission needs to understand the capabilities and limitations of these methods when evaluating funding proposals or regulatory submissions for AI-driven drug discovery tools. The ergofluids project, which tested Koopman-operator methods for drug transport modeling, is relevant to the EU's cancer mission. The project failed its first real-data gate and reported that result directly. This is the kind of negative result that policy-makers rarely see, but which is essential for calibrating expectations about computational models in oncology. My work on topological data analysis for hERG cardiotoxicity showed that a method promoted in the literature does not beat a simple baseline. This finding has direct implications for how the Commission evaluates claims about AI methods in drug safety assessment. I can bring this critical perspective to the evaluation of research proposals and regulatory dossiers. SHORT ESSAY: DIVERSITY AND INTERNATIONAL PERSPECTIVE I am a Nigerian national who has studied and worked in two countries with very different health systems. Nigeria has a pharmacist-to-population ratio of roughly 1 to 10,000. Germany has roughly 1 to 1,500. I have practiced clinical pharmacy in both settings. This experience gives me a concrete understanding of how digital health tools must adapt to infrastructure constraints, supply chain reliability, and workforce capacity. At the Hasso Plattner Institute, I am the only Nigerian student in my cohort. I am also the only student with a pharmacy background in a programme focused on computer science and health informatics. This combination is rare. It means I can translate between clinical language and technical language, between the logic of a regulatory submission and the logic of a machine learning pipeline. The Commission's work on global health, on the digital transition in Africa, and on the EU-Africa partnership all require staff who understand both contexts. I have built research collaborations across continents. I have managed projects with no institutional support, which taught me to be precise about what I can deliver and honest about what I cannot. That discipline is directly relevant to policy work, where overpromising on technology is a recurring risk. I want to contribute to a cohort that reflects the diversity of the EU's partners and the complexity of the challenges the Commission addresses. My background is not typical for a Blue Book candidate. That is precisely why it is valuable. CHECKLIST - [ ] Valid international passport (scan, not expired) - [ ] University degree certificate and transcript (B.Pharm, University of Ibadan) - [ ] Proof of current enrolment (M.Sc. Digital Health, Hasso Plattner Institute, Winter 2026/27) - [ ] Proof of English language proficiency (no IELTS/TOEFL required, but may need a letter or certificate) - [ ] Curriculum vitae (Europass format recommended) - [ ] Motivation letter (300-500 words, tailored to Blue Book Traineeship) - [ ] Short essays (200-350 words each, as specified by the application portal) - [ ] Copy of ORCID profile page - [ ] Copy of GitHub profile page - [ ] Copy of personal website (zyco.org) - [ ] List of preprints and publications with DOIs or links - [ ] Endorsement letters or contact details for referees (Berridge, Gershman, Daw, Mattar) - [ ] Proof of any exchange programmes or workshops attended - [ ] Completed online application form on the EC Blue Book portal EDITOR NOTES - Eligibility risk: The programme is open to non-EU nationals but the number of places is limited. Confirm the exact quota for non-EU candidates in the 2027 cohort. The profile does not specify whether the applicant has ever held a residence permit in an EU country beyond the student visa for Germany. This may affect eligibility for certain tracks. - Fact verification: The profile states the M.Sc. Digital Health programme starts in Winter Semester 2026/27. Confirm the exact start date and whether the applicant will be enrolled at the time of the traineeship (typically March or October 2027). If the traineeship overlaps with the M.Sc., the applicant must confirm that the programme allows a leave of absence or that the traineeship can be completed during a break. - Gap: The profile does not include any prior work experience in policy, government, or international organisations. The motivation letter should address this gap by framing the applicant's independent research management as equivalent to policy-relevant project management. The applicant should prepare a concrete example of a time they had to navigate a regulatory or compliance issue in their research. - Gap: The profile does not specify the applicant's age at the time of application. The programme has no age limit, but the applicant should confirm this on the official programme page, not the third-party aggregator site. - Gap: The profile does not include any evidence of language skills beyond English. The programme may require knowledge of a second EU language. The applicant should check the specific requirements for the ADMIN track.